TARGET ENGAGEMENT AND PHARMACODYNAMIC MOLECULAR MECHANISM EVALUATION IN A PHASE 1B STUDY OF THE NUCLEOTIDE-BINDING OLIGOMERIZATION DOMAIN, LEUCINE RICH REPEAT CONTAINING X1 (NLRX1) AGONIST NX-13 IN ULCERATIVE COLITIS

Bram Verstockt  ¹     Severine Vermeire  ²     Britta Siegmund  ³     Florian Rieder  ⁴     Stefan Schreiber  ⁵     Simon Lichtiger  ⁶     Rebecca Mosig  ⁶     Fabio Cataldi  ⁶     Silvio Danese  ^7    
1 University Hospitals Leuven and KU Leuven, Translational Research in Gastrointestinal Disorders - IB, Leuven, Belgium
² University Hospital Leuven, Leuven, Belgium
³ Charité - Universitätsmedizin Berlin, Berlin, Germany
⁴ Cleveland Clinic Foundation, Cleveland Heights, United States
⁵ University Hospital Schleswig-Holstein, Kiel, Germany
⁶ Landos Biopharma, Inc, Blacksburg, United States
⁷ Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Netherlands

Topic
IBD

Session
PP 05 IBD (Posters)

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)